EP3589272A4 - Verfahren zur prophylaktischen prävention, verlangsamung der progression oder behandlung von morbus alzheimer - Google Patents

Verfahren zur prophylaktischen prävention, verlangsamung der progression oder behandlung von morbus alzheimer Download PDF

Info

Publication number
EP3589272A4
EP3589272A4 EP18761409.4A EP18761409A EP3589272A4 EP 3589272 A4 EP3589272 A4 EP 3589272A4 EP 18761409 A EP18761409 A EP 18761409A EP 3589272 A4 EP3589272 A4 EP 3589272A4
Authority
EP
European Patent Office
Prior art keywords
slowing
progression
disease
methods
treating alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP18761409.4A
Other languages
English (en)
French (fr)
Other versions
EP3589272A1 (de
Inventor
Hollis Bryan BREWER, Jr.
Michael M. MATIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HDL Therapeutics Inc
Original Assignee
HDL Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/876,808 external-priority patent/US20190021674A1/en
Application filed by HDL Therapeutics Inc filed Critical HDL Therapeutics Inc
Priority claimed from PCT/US2018/020502 external-priority patent/WO2018160868A1/en
Publication of EP3589272A1 publication Critical patent/EP3589272A1/de
Publication of EP3589272A4 publication Critical patent/EP3589272A4/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0042—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Disabilities (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
EP18761409.4A 2017-03-01 2018-03-01 Verfahren zur prophylaktischen prävention, verlangsamung der progression oder behandlung von morbus alzheimer Ceased EP3589272A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762465262P 2017-03-01 2017-03-01
US201762516100P 2017-06-06 2017-06-06
US201762537581P 2017-07-27 2017-07-27
US15/876,808 US20190021674A1 (en) 2017-01-23 2018-01-22 Methods for Treating Cholesterol-Related Diseases
PCT/US2018/020502 WO2018160868A1 (en) 2017-03-01 2018-03-01 Methods for prophylactically preventing, slowing the progression of, or treating alzheimer's disease

Publications (2)

Publication Number Publication Date
EP3589272A1 EP3589272A1 (de) 2020-01-08
EP3589272A4 true EP3589272A4 (de) 2020-11-25

Family

ID=67682480

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18761409.4A Ceased EP3589272A4 (de) 2017-03-01 2018-03-01 Verfahren zur prophylaktischen prävention, verlangsamung der progression oder behandlung von morbus alzheimer

Country Status (5)

Country Link
EP (1) EP3589272A4 (de)
JP (2) JP2020509036A (de)
CN (1) CN110545797A (de)
AU (1) AU2018226803A1 (de)
CA (1) CA3053491A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3099999A1 (en) * 2018-05-11 2019-11-14 Hdl Therapeutics, Inc. Methods for prophylactically preventing, slowing the progression of, or treating cerebral amyloid angiopathy, alzheimer's disease and/or acute stroke
CN116662835A (zh) 2022-02-18 2023-08-29 医疗研究开发有限公司 分层方法以及分层装置

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106556A1 (en) * 2002-08-26 2004-06-03 Yanhong Zhu Method of treating and preventing alzheimer disease through administration of delipidated protein and lipoprotein particles
US20050004004A1 (en) * 2003-07-03 2005-01-06 Marc Bellotti Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US20080146642A1 (en) * 2006-10-12 2008-06-19 Xianqi Kong Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US9580494B2 (en) * 2007-05-14 2017-02-28 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2463304B1 (de) * 2007-02-23 2014-04-30 The United States of America as represented by the Secretary, Department of Health and Human Services Monoklonale Antikörper zur Neutralisierung von Anthrax-Toxinen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106556A1 (en) * 2002-08-26 2004-06-03 Yanhong Zhu Method of treating and preventing alzheimer disease through administration of delipidated protein and lipoprotein particles
US20050004004A1 (en) * 2003-07-03 2005-01-06 Marc Bellotti Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US20080146642A1 (en) * 2006-10-12 2008-06-19 Xianqi Kong Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US9580494B2 (en) * 2007-05-14 2017-02-28 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRUNO P IMBIMBO: "Beta-amyloid immunization approaches for Alzheimer's disease", DRUG DEVELOPMENT RESEARCH, NEW YORK, NY, US, vol. 56, 1 January 2002 (2002-01-01), pages 150 - 162, XP002426086, ISSN: 0272-4391, DOI: 10.1002/DDR.10070 *

Also Published As

Publication number Publication date
CN110545797A (zh) 2019-12-06
CA3053491A1 (en) 2018-09-07
EP3589272A1 (de) 2020-01-08
JP2020509036A (ja) 2020-03-26
JP2023071648A (ja) 2023-05-23
AU2018226803A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
EP3481402A4 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung einer krankheit
EP3634953A4 (de) Verbindungen zur behandlung von morbus huntington
EP3644996A4 (de) Verfahren zur behandlung von morbus huntington
EP3645121A4 (de) Verfahren zur behandlung von morbus huntington
EP3675859A4 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von krankheiten
EP3448874A4 (de) Zusammensetzungen zur behandlung einer erkrankung
EP3448875A4 (de) Zusammensetzungen zur behandlung einer erkrankung
EP3448987A4 (de) Zusammensetzungen zur behandlung einer erkrankung
EP3484504A4 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von krankheiten
EP3570844A4 (de) Azolopyrimidin zur behandlung von krebsbedingten erkrankungen
EP3386511A4 (de) Verfahren zur behandlung von morbus huntington
EP3140403A4 (de) Vorbeugung und behandlung von alzheimerkrankheit durch gemonänderung mithilfe eines crispr/cas-systems
EP3464313A4 (de) 5'-cyclo-phosphonatmodifizierte nukleotide
EP3268086A4 (de) Lsd zur behandlung von morbus alzheimer
EP3515505A4 (de) Aav-behandlung von morbus alzheimer
EP3698649A4 (de) Mittel zur vorbeugung oder linderung von morbus alzheimer
IL263433A (en) Methods for treating Alzheimer's disease
EP3377118A4 (de) Verfahren zur behandlung von morbus alzheimer und zugehörigen erkrankungen
WO2019173795A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
EP3633372A4 (de) Biomarker für morbus alzheimer
EP3458036A4 (de) Verfahren zur behandlung oder vorbeugung von morbus alzheimer und verwandten erkrankungen
EP3429598A4 (de) Zusammensetzungen und verfahren zur behandlung von beta-catenin-assoziierter erkrankung oder störung
EP3502248A4 (de) Antikörper gegen hmgb1 und zusammensetzung damit zur behandlung oder vorbeugung von morbus alzheimer
ZA201805407B (en) Composition for the prevention or treatment of neurodegenerative diseases.
EP3261446A4 (de) Verfahren und zusammensetzungen zur behandlung oder prävention von morbus parkinson

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190828

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0009127000

Ipc: A61K0038180000

A4 Supplementary search report drawn up and despatched

Effective date: 20201028

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/18 20060101AFI20201022BHEP

Ipc: A61K 38/30 20060101ALI20201022BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210917

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20230407